A LinkedIn post from Pulnovo Medical highlights plans to feature its Pulmonary Artery Denervation, or PADN, clinical trials at CRT 2026 in Washington, D.C. The post points to two late-breaking presentations focused on applications in pulmonary hypertension, PH, and heart failure, HF, including the PULNOVO PULSE LHD trial.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests Pulnovo is positioning PADN as a potential interventional option in PH and HF related to left heart disease, an area with significant unmet need and large addressable markets. For investors, visibility at a major cardiovascular meeting could help validate the technology, attract clinical collaborators, and potentially support future fundraising or partnership discussions if trial data prove favorable.